Trial Profile
First-line cisplatin + S-1 +/- nimotuzumab in patients with advanced gastric cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Sep 2015
Price :
$35
*
At a glance
- Drugs Nimotuzumab (Primary) ; Cisplatin; Gimeracil/oteracil/tegafur
- Indications Gastric cancer
- Focus Therapeutic Use
- 05 Jun 2012 Interim results presented at the 48th Annual Meeting of the American Society of Clinical Oncology.
- 22 Jun 2011 New trial record
- 07 Jun 2011 Interim results presented at the 47th Annual Meeting of the American Society of Clinical Oncology.